

# CITATION REPORT

List of articles citing

**Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study**

**DOI: 10.1097/00042737-200411000-00014**

**European Journal of Gastroenterology and Hepatology  
, 2004, 16, 1167-71.**

**Source:** <https://exaly.com/paper-pdf/37744565/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	A comparative study of goblet cell and pancreatic exocrine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. <b>2005</b> , 11, 890-7		25
110	Infliximab: Use in Inflammatory Bowel Disease. <b>2005</b> , 8, 187-196		26
109	Early surgery for the treatment of toxic megacolon. <b>2005</b> , 72, 146-9		12
108	Infliximab use in Crohn's disease. <b>2005</b> , 5, 589-99		7
107	Defects in mucosal immunity leading to ulcerative colitis. <b>2005</b> , 206, 296-305		137
106	How important is onset of action in ulcerative colitis therapy?. <b>2005</b> , 65, 2069-83		3
105	Treatment of Crohn's disease: the "long" of it. <b>2005</b> , 128, 2164-6		4
104	Infliximab for ulcerative colitis: finally some answers. <b>2005</b> , 128, 2161-4		23
103	Infliximab for induction and maintenance therapy for ulcerative colitis. <b>2005</b> , 353, 2462-76		2906
102	Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. <b>2006</b> , 41, 1056-63		71
101	Infliximab in ulcerative colitis. <b>2006</b> , 35, 821-36		13
100	Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. <b>2006</b> , CD005112		87
99	Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. <b>2006</b> , 66, 2059-65		12
98	Use in Ulcerative Colitis. 70-73		
97	Bibliography. Current world literature. Small intestine. <b>2006</b> , 22, 171-83		
96	Review article: Infliximab therapy for inflammatory bowel disease--seven years on. <b>2006</b> , 23, 451-63		189
95	Systematic review: Infliximab therapy in ulcerative colitis. <b>2007</b> , 25, 19-37		100

94	Basic immunosuppressive drugs outside solid organ transplantation. <b>2006</b> , 15, 267-91	3
93	Infliximab and ulcerative colitis. <b>2006</b> , 6, 401-8	10
92	TNF-alpha Inhibitors. <b>2006</b> ,	3
91	A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. <b>2006</b> , 55, 1255-62	313
90	Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. <b>2006</b> , 66, 249-59	33
89	Treatment with biologic therapies and the risk of cancer in patients with IBD. <b>2007</b> , 4, 78-91	35
88	[Use of infliximab in ulcerative colitis]. <b>2007</b> , 45, 907-11	2
87	The role of TNFalpha in ulcerative colitis. <b>2007</b> , 47, 930-41	105
86	A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. <b>2007</b> , 132, 763-86	724
85	Infliximab therapy in children and adolescents with inflammatory bowel disease. <b>2007</b> , 67, 1703-23	30
84	Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. <b>2007</b> , 25, 787-96	36
83	Review article: the management of steroid dependency in ulcerative colitis. <b>2007</b> , 26, 779-94	43
82	A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. <b>2007</b> , 26, 411-9	108
81	[Ulcerative colitis and anti-TNFalpha]. <b>2007</b> , 31, 84-7	
80	Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. <b>2008</b> , 51, 1202-7; discussion 1207-10	216
79	Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: the price we have to pay?. <b>2008</b> , 14, 1019-21	5
78	US estimates of hospitalized pediatric patients with ulcerative colitis: implications for multicenter clinical studies. <b>2008</b> , 14, 1253-8	3
77	Is there a role for infliximab in severe ulcerative colitis?: the European experience. <b>2008</b> , 14 Suppl 2, S234-5	1

76	Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. <b>2008</b> , 14 Suppl 2, S232-3	1
75	Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. <b>2008</b> , 28, 966-72	77
74	European evidence-based Consensus on the management of ulcerative colitis: Current management. <b>2008</b> , 2, 24-62	37 <sup>1</sup>
73	Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. <b>2008</b> , 103, 637-42	79
72	A review of infliximab use in ulcerative colitis. <b>2008</b> , 30, 223-30	42
71	Severe ulcerative colitis: present medical treatment strategies. <b>2008</b> , 9, 447-57	6
70	Is there a role for infliximab in severe ulcerative colitis?. <b>2008</b> , 14, S234-S235	
69	Is there a role for infliximab in the treatment of severe ulcerative colitis?. <b>2008</b> , 14, S232-S233	1
68	Review and clinical perspectives for the use of infliximab in ulcerative colitis. <b>2008</b> , 22, 261-72	7
67	Infliximab in ulcerative colitis. <b>2008</b> , 2, 379-88	21
66	Current strategies for the treatment of ulcerative colitis. <b>2009</b> , 3, 65-72	11
65	Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. <i>Clinical and Experimental Gastroenterology</i> , <b>2009</b> , 149	3 <sup>1</sup>
64	Infliximab for the treatment of ulcerative colitis. <b>2009</b> , 3, 219-29	5
63	Treatment of severe ulcerative colitis: differences in elderly patients?. <b>2009</b> , 27, 315-21	13
62	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. <b>2010</b> , 16 Suppl 1, S1-11	14
61	Review article: the optimal medical management of acute severe ulcerative colitis. <b>2010</b> , 32, 615-27	31
60	Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. <b>2010</b> , 105, 1811-9	119
59	Current therapeutic approaches in inflammatory bowel disease. <b>2010</b> , 16, 3668-83	25

58	Efficacy and safety of drugs for ulcerative colitis. <b>2010</b> , 9, 573-92		24
57	A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. <b>2010</b> , 4, 221-56		68
56	The role of biologics in ulcerative colitis. <b>2010</b> , 28, 497-500		2
55	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. <b>2011</b> , 43, 1-20		101
54	Cytokine Networks in Ulcerative Colitis. <b>2011</b> , 2011, 1-5		28
53	A meta-analysis of the therapeutic effects of tumor necrosis factor- $\beta$ blockers on ulcerative colitis. <b>2011</b> , 67, 759-66		27
52	Update on the management of ulcerative colitis. <b>2011</b> , 13, 475-85		14
51	[Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. <b>2011</b> , 49, 1276-341		127
50	Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. <i>Clinical and Experimental Gastroenterology</i> , <b>2011</b> , 4, 9-17	3.1	9
49	Strategies for the care of adults hospitalized for active ulcerative colitis. <b>2012</b> , 10, 1315-1325.e4		46
48	Surgical treatment of ulcerative colitis in the biologic therapy era. <b>2012</b> , 18, 1861-70		32
47	What's the next best cytokine target in IBD?. <b>2012</b> , 18, 2180-9		23
46	Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. <b>2012</b> , 18, 212-8		42
45	Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. <b>2013</b> , 38, 377-87		59
44	Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article. <b>2013</b> , 48, 131-5		6
43	Adalimumab in ulcerative colitis: ready for prime time. <b>2013</b> , 45, 8-13		9
42	Treatment of Ulcerative Colitis in the Elderly: A Systematic Review. <b>2013</b> , 6, 1-26		3
41	Randomised controlled trial. Comparison Of infliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). <b>2014</b> , 4, e005091		23

40	Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. <b>2014</b> , 57, 83-90		27
39	A new pediatric protocol for rapid desensitization to monoclonal antibodies. <b>2014</b> , 165, 214-8		9
38	The importance of validating proposed genetic profiles in IBD. <b>2014</b> , 275, 481-3		
37	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. <b>2014</b> , 8, 571-81		54
36	Optimal management of steroid-dependent ulcerative colitis. <i>Clinical and Experimental Gastroenterology</i> , <b>2015</b> , 8, 293-302	3.1	12
35	Biological therapy for ulcerative colitis. <b>2015</b> , 3, 103-9		27
34	Efficacy and safety of tumor necrosis factor- $\alpha$ blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. <b>2015</b> , 23, 1-10		6
33	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <b>2015</b> , 47, 356-64		29
32	Review article: the practical management of acute severe ulcerative colitis. <b>2016</b> , 43, 482-513		55
31	Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. <b>2016</b> , 12, 1693-1704		12
30	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. <b>2017</b> , 45, 617-630		50
29	Update on the Use of Biologic Therapy in Ulcerative Colitis. <b>2017</b> , 15, 155-167		10
28	Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab. <b>2017</b> , 429-433		0
27	Acute severe ulcerative colitis: State of the art treatment. <b>2018</b> , 32-33, 59-69		20
26	Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. <b>2019</b> , 148, 104455		15
25	Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?. <b>2019</b> , 13, 23-31		7
24	Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. <b>2019</b> , 8,		7
23	Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. <b>2020</b> , 51, 8-33		14

22	Concepts in Inflammatory Bowel Disease Management. <b>2019</b> , 1888-1918	1
21	GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. <b>2020</b> , 43 Suppl 1, 1-57	3
20	Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. <b>2014</b> , 9, e86692	32
19	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. <b>2016</b> , 20, 1-326	32
18	Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). <b>2016</b> , 20, 1-320	35
17	Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. <b>2008</b> , 14, 2544-9	28
16	High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. <b>2020</b> , 24, 1-10	4
15	VALIDATION OF TNF AS A DRUG TARGET IN INFLAMMATORY BOWEL DISEASE. <b>2007</b> , 83-102	
14	Ulcerative Colitis. <b>2010</b> , 232-247	
13	Biologic Therapy of Ulcerative Colitis: Infliximab, Adlimumab, Golimumab. <b>2012</b> , 495-502	
12	Infliximab for Ulcerative Colitis. <b>2014</b> , 175-184	
11	Principles of Medical Management of Ulcerative Colitis. <b>2014</b> , 31-44	
10	The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review. <b>2015</b> , 3-28	
9	[Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. <i>Terapevticheskii Arkhiv</i> , <b>2015</b> , 87, 34-38	0.9 4
8	Gastroenterologie. <b>2017</b> , 185-264	
7	Infliximab in dermatology, gastroenterology, and off-label use. <b>2006</b> , 83-99	
6	Indications for use of infliximab in inflammatory bowel disease. 165-182	
5	Refractory ulcerative colitis: the aggressive approach. 264-271	

4	Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. <i>Clinical and Experimental Gastroenterology</i> , <b>2009</b> , 2, 149-61	3.1	4
3	A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , <b>2021</b> , 17, 59-66	0.7	
2	Rescue therapies for steroid-refractory acute severe ulcerative colitis: A review.		0
1	Clinical trials and future perspectives of antiinflammatory agents. <b>2023</b> , 331-386		0